淋巴瘤中期FDG-PET成像
本文综述了淋巴瘤治疗中期FDG-PET/CT(iPET)的原理,重点阐述了从CT解剖学肿瘤缩小评估向PET功能成像评估个体肿瘤化疗敏感性的转变。综述了iPET在不同淋巴瘤亚型中的预后或预测作用,并回顾了iPET反应适应性临床试验及其临床获益。
要点
- iPET已成为早期和晚期霍奇金淋巴瘤的标准治疗,未来可能扩展至原发纵隔B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤。
- 不同淋巴瘤实体的FDG摄取模式各异,判读需结合肿瘤架构及微环境中肿瘤性与非肿瘤性炎症细胞的比例。
- iPET反应适应性临床试验显示了该策略相较于标准非PET适应性治疗的临床获益。
核心结论
- iPET-adapted策略已成为早期和晚期霍奇金淋巴瘤的标准治疗,未来可能扩展至原发纵隔B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤。
研究设计与样本
- 本文为综述,回顾了iPET在淋巴瘤中的原理、预后或预测作用、不同淋巴瘤实体的FDG摄取模式、iPET反应适应性临床试验及其临床获益。
主要发现
- 大多数淋巴瘤亚型存在大量证据强调iPET在一线化疗期间早期化疗反应中的作用,近期有更多报告关注iPET在复发或难治性淋巴瘤中预测治疗结局的作用。
- 不同淋巴瘤实体观察到不同的FDG摄取模式,FDG-PET扫描的判读应在肿瘤架构和细胞群体(特别是组织微环境中存在的肿瘤性与非肿瘤性炎症细胞)的背景下进行。
- 综述回顾了iPET反应适应性临床试验及该策略相较于标准非PET适应性治疗的临床获益,并推断FDG-PET图像判读的可重复性及基于FDG-PET结果及时调整治疗在日常临床实践中的可行性。
临床怎么用
- iPET-adapted策略已成为早期和晚期霍奇金淋巴瘤的标准治疗。
- 作者认为未来该策略可能扩展至原发纵隔B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma. A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory lymphoma to predict treatment outcome. Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment. In the second part of the article, the authors reviewed the iPET-response adapted clinical trials and the clinical benefits of this strategy compared to standard non-PET adapted therapy. In particular, the authors extrapolated the reproducibility of FDG-PET image interpretation and the feasibility of a timely treatment adaptation based on FDG-PET results in daily clinical practice. This is essential for the reader, as the iPET-adapted strategy has become the standard of care in both early- and advanced-stage Hodgkin lymphoma, and, in the future, probably this strategy will be expanded to primary mediastinal B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma.
引用
- Gallamini A, Zwarthoed C. Interim FDG-PET Imaging in Lymphoma. Semin Nucl Med. 2017. PMID: 29195613. doi:10.1053/j.semnuclmed.2017.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。